Experience with antilymphocyte globulin in 144 renal transplant recipients.
In patients receiving cadaveric kidneys and treated with antilymphocyte globulin (ALG) the one-year graft survival 59%. The corresponding figures with living related donors were 87% and 83%, respectively. Side effects of ALG, of which allergic reactions were the most common, prompted its withdrawal in 33% of the cases. All patients studied developed antibodies against horse gammaglobulin when tested with a passive haemagglutination inhibition technique. ALG seems to act upon the T-cells since the number of cells forming rosettes with sheep red blood cells was reduced.
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D006085:Graft Survival / Q000187:drug effects; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D016030:Kidney Transplantation; D013997:Time Factors; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum